CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy

Yiyi Yan, Siyu Cao, Xin Liu, Susan M. Harrington, Wendy E. Bindeman, Alex Adjei, Jin Sung Jang, Jin Jen, Ying Li, Pritha Chanana, Aaron Mansfield, Sean S. Park, Svetomir Nenad Markovic, Roxana S Dronca, Haidong M Dong

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Although immune checkpoint inhibitors have resulted in durable clinical benefits in a subset of patients with advanced cancer, some patients who did not respond to initial anti-PD-1 therapy have been found to benefit from the addition of salvage chemotherapy. However, the mechanism responsible for the successful chemoimmunotherapy is not completely understood. Here we show that a subset of circulating CD8+ T cells expressing the chemokine receptor CX3CR1 are able to withstand the toxicity of chemotherapy and are increased in patients with metastatic melanoma who responded to chemoimmunotherapy (paclitaxel and carboplatin plus PD-1 blockade). These CX3CR1+CD8+ T cells have effector memory phenotypes and the ability to efflux chemotherapy drugs via the ABCB1 transporter. In line with clinical observation, our preclinical models identified an optimal sequencing of chemoimmunotherapy that resulted in an increase of CX3CR1+CD8+ T cells. Taken together, we found a subset of PD-1 therapy-responsive CD8+ T cells that were capable of withstanding chemotherapy and executing tumor rejection with their unique abilities of drug efflux (ABCB1), cytolytic activity (granzyme B and perforin), and migration to and retention (CX3CR1 and CD11a) at tumor sites. Future strategies to monitor and increase the frequency of CX3CR1+CD8+ T cells may help to design effective chemoimmunotherapy to overcome cancer resistance to immune checkpoint blockade therapy.

Original languageEnglish (US)
JournalJCI insight
Volume3
Issue number8
DOIs
StatePublished - Apr 19 2018

Fingerprint

T-Lymphocytes
Drug Therapy
Aptitude
Neoplasms
Therapeutics
Chemokine Receptors
Carboplatin
Paclitaxel
Pharmaceutical Preparations
Melanoma
Observation
Phenotype

Keywords

  • Cancer immunotherapy
  • Cellular immune response
  • Immunology
  • Oncology
  • T cells

Cite this

CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. / Yan, Yiyi; Cao, Siyu; Liu, Xin; Harrington, Susan M.; Bindeman, Wendy E.; Adjei, Alex; Jang, Jin Sung; Jen, Jin; Li, Ying; Chanana, Pritha; Mansfield, Aaron; Park, Sean S.; Markovic, Svetomir Nenad; Dronca, Roxana S; Dong, Haidong M.

In: JCI insight, Vol. 3, No. 8, 19.04.2018.

Research output: Contribution to journalArticle

Yan, Yiyi ; Cao, Siyu ; Liu, Xin ; Harrington, Susan M. ; Bindeman, Wendy E. ; Adjei, Alex ; Jang, Jin Sung ; Jen, Jin ; Li, Ying ; Chanana, Pritha ; Mansfield, Aaron ; Park, Sean S. ; Markovic, Svetomir Nenad ; Dronca, Roxana S ; Dong, Haidong M. / CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. In: JCI insight. 2018 ; Vol. 3, No. 8.
@article{3f53298b251747b5ab00bce4208f4b43,
title = "CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy",
abstract = "Although immune checkpoint inhibitors have resulted in durable clinical benefits in a subset of patients with advanced cancer, some patients who did not respond to initial anti-PD-1 therapy have been found to benefit from the addition of salvage chemotherapy. However, the mechanism responsible for the successful chemoimmunotherapy is not completely understood. Here we show that a subset of circulating CD8+ T cells expressing the chemokine receptor CX3CR1 are able to withstand the toxicity of chemotherapy and are increased in patients with metastatic melanoma who responded to chemoimmunotherapy (paclitaxel and carboplatin plus PD-1 blockade). These CX3CR1+CD8+ T cells have effector memory phenotypes and the ability to efflux chemotherapy drugs via the ABCB1 transporter. In line with clinical observation, our preclinical models identified an optimal sequencing of chemoimmunotherapy that resulted in an increase of CX3CR1+CD8+ T cells. Taken together, we found a subset of PD-1 therapy-responsive CD8+ T cells that were capable of withstanding chemotherapy and executing tumor rejection with their unique abilities of drug efflux (ABCB1), cytolytic activity (granzyme B and perforin), and migration to and retention (CX3CR1 and CD11a) at tumor sites. Future strategies to monitor and increase the frequency of CX3CR1+CD8+ T cells may help to design effective chemoimmunotherapy to overcome cancer resistance to immune checkpoint blockade therapy.",
keywords = "Cancer immunotherapy, Cellular immune response, Immunology, Oncology, T cells",
author = "Yiyi Yan and Siyu Cao and Xin Liu and Harrington, {Susan M.} and Bindeman, {Wendy E.} and Alex Adjei and Jang, {Jin Sung} and Jin Jen and Ying Li and Pritha Chanana and Aaron Mansfield and Park, {Sean S.} and Markovic, {Svetomir Nenad} and Dronca, {Roxana S} and Dong, {Haidong M}",
year = "2018",
month = "4",
day = "19",
doi = "10.1172/jci.insight.97828",
language = "English (US)",
volume = "3",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "8",

}

TY - JOUR

T1 - CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy

AU - Yan, Yiyi

AU - Cao, Siyu

AU - Liu, Xin

AU - Harrington, Susan M.

AU - Bindeman, Wendy E.

AU - Adjei, Alex

AU - Jang, Jin Sung

AU - Jen, Jin

AU - Li, Ying

AU - Chanana, Pritha

AU - Mansfield, Aaron

AU - Park, Sean S.

AU - Markovic, Svetomir Nenad

AU - Dronca, Roxana S

AU - Dong, Haidong M

PY - 2018/4/19

Y1 - 2018/4/19

N2 - Although immune checkpoint inhibitors have resulted in durable clinical benefits in a subset of patients with advanced cancer, some patients who did not respond to initial anti-PD-1 therapy have been found to benefit from the addition of salvage chemotherapy. However, the mechanism responsible for the successful chemoimmunotherapy is not completely understood. Here we show that a subset of circulating CD8+ T cells expressing the chemokine receptor CX3CR1 are able to withstand the toxicity of chemotherapy and are increased in patients with metastatic melanoma who responded to chemoimmunotherapy (paclitaxel and carboplatin plus PD-1 blockade). These CX3CR1+CD8+ T cells have effector memory phenotypes and the ability to efflux chemotherapy drugs via the ABCB1 transporter. In line with clinical observation, our preclinical models identified an optimal sequencing of chemoimmunotherapy that resulted in an increase of CX3CR1+CD8+ T cells. Taken together, we found a subset of PD-1 therapy-responsive CD8+ T cells that were capable of withstanding chemotherapy and executing tumor rejection with their unique abilities of drug efflux (ABCB1), cytolytic activity (granzyme B and perforin), and migration to and retention (CX3CR1 and CD11a) at tumor sites. Future strategies to monitor and increase the frequency of CX3CR1+CD8+ T cells may help to design effective chemoimmunotherapy to overcome cancer resistance to immune checkpoint blockade therapy.

AB - Although immune checkpoint inhibitors have resulted in durable clinical benefits in a subset of patients with advanced cancer, some patients who did not respond to initial anti-PD-1 therapy have been found to benefit from the addition of salvage chemotherapy. However, the mechanism responsible for the successful chemoimmunotherapy is not completely understood. Here we show that a subset of circulating CD8+ T cells expressing the chemokine receptor CX3CR1 are able to withstand the toxicity of chemotherapy and are increased in patients with metastatic melanoma who responded to chemoimmunotherapy (paclitaxel and carboplatin plus PD-1 blockade). These CX3CR1+CD8+ T cells have effector memory phenotypes and the ability to efflux chemotherapy drugs via the ABCB1 transporter. In line with clinical observation, our preclinical models identified an optimal sequencing of chemoimmunotherapy that resulted in an increase of CX3CR1+CD8+ T cells. Taken together, we found a subset of PD-1 therapy-responsive CD8+ T cells that were capable of withstanding chemotherapy and executing tumor rejection with their unique abilities of drug efflux (ABCB1), cytolytic activity (granzyme B and perforin), and migration to and retention (CX3CR1 and CD11a) at tumor sites. Future strategies to monitor and increase the frequency of CX3CR1+CD8+ T cells may help to design effective chemoimmunotherapy to overcome cancer resistance to immune checkpoint blockade therapy.

KW - Cancer immunotherapy

KW - Cellular immune response

KW - Immunology

KW - Oncology

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=85051123523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051123523&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.97828

DO - 10.1172/jci.insight.97828

M3 - Article

C2 - 29669928

AN - SCOPUS:85051123523

VL - 3

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 8

ER -